Hospira, Inc.

Hospira, Inc.

Hospira, Inc.

Overview
Date Founded

2003

Headquarters

275 North Field Drive, Lake Forest, IL, 60045, USA

Type of Company

Private

Employees (Worldwide)

10K - 1M

Industries

Pharmaceuticals
Wholesale: Medical Supplies & Pharmaceuticals
Medical Products & Equipment
Medical Support Services

Company Description

Hospira, Inc. provides injectable drugs and infusion technologies. It offers drugs, IV sets and clinical integration, infusion pumps, clinical software and implementation services. The company was founded on September 16, 2003 and is headquartered in Lake Forest, IL.

Contact Data
Trying to get in touch with decision makers at Hospira, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer & Director

Chief Commercial Officer & Senior Vice President

Senior Vice President, Quality

Global Process Owner Procure to PAY

President

Senior Account Executive

Senior Account Executive

Senior Account Executive

Senior Account Executive

Senior Account Executive

Board of Directors

Chief Executive Officer at Fenton & Associates LLC

Former Executive Vice President at BellSouth LLC

Former Vice President-Engineering at General Electric Company

Paths to Hospira, Inc.
Potential Connections via
Relationship Science
You
Hospira, Inc.
Recent Transactions
Details Hidden

Pfizer, Inc. purchases Hospira, Inc.

Details Hidden

Premier Healthcare Solutions, Inc., Premier, Inc. purchase TheraDoc, Inc. from Hospira, Inc.

Details Hidden

Hospira, Inc. purchases Javelin Pharmaceuticals, Inc.

Transaction Advisors
Legal Advisor

Advised onHospira, Inc. purchases Mayne Pharma Ltd.

Investment Advisor

Advised onPfizer, Inc. purchases Hospira, Inc.

Investment Advisor

Advised onHospira, Inc., Hospira Holdings (SA) Pty Ltd. purchase Hospira Adelaide Pty Ltd.

Global Chair, Mergers & Acquisition Practice

Advised onHospira, Inc. purchases Orchid Chemicals & Pharmaceuticals Ltd. /Injection Business from Orchid Pharma Ltd.

Legal Advisor

Advised onPfizer, Inc. purchases Hospira, Inc.

Legal Advisor

Advised onHospira, Inc. purchases Javelin Pharmaceuticals, Inc.

Advisors & Consultants
Legal Advisor

Partner at Baker & McKenzie LLP

Legal Advisor

Partner at Baker & McKenzie LLP

Legal Advisor

Global Head of Intellectual Property & General Counsel for US at Hikma Pharmaceuticals Plc

Clients

The Medicines Co We are a global pharmaceutical company focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. In the United States, we have three marketed products, Angiomax® (bivalirudin) for Injection, Cleviprex® (clevidipine) Injectable Emulsion, and Argatroban Injection, 50 mg per 50 mL†. We also have a pipeline of acute and intensive care hospital products in development, including three late-stage development product candidates, cangrelor, oritavancin and MDCO-157, and two early stage development product candidates, MDCO-2010 and MDCO-216. We believe that Angiomax, Cleviprex and our products in development possess favorable attributes that can satisfy unmet medical needs in the acute | intensive care hospital product market and offer, or, in the case of our products in development, have the potential to offer, improved performance to hospital businesses. The Company is publicly traded on the Nasdaq exchange under the ticker symbol MDCO. It was founded in 1996 and employs approximately 425 professionals.

Key Stats and Financials As of
Market Capitalization
$15.6B
Total Enterprise Value
Earnings Per Share
Non-Profit Donations & Grants
Investments
Details Hidden

ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA.

Suppliers
BioTime Inc. Medical Support Services | ALAMEDA, CA

BioTime, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Alameda, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Hospira, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Hospira, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Hospira, Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://news.relsci.com/organization/hospira-inc-89904
  • https://news.relsci.com/organization/hospira-inc-89904